ArticleFrontiers in immunology2025
Identification of prognostic hub genes and functional role of BAIAP2L2 in prostate cancer progression: a transcriptomic and experimental study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is a prevalent malignancy in men, and understanding its molecular mechanisms is crucial for identifying therapeutic targets. Methods: Transcriptomic data from prostate tumors and matched healthy tissues were obtained from The Cancer Genome Atlas (TCGA). Differential expression analysis using the DESeq2 algorithm identified differentially expressed genes (DEGs). Cox proportional hazards regression was used to evaluate prognostic significance. Clinical validation involved comparing tumor specimens with normal tissues, focusing on BAIAP2L2, which showed significant differential expression and was further examined via immunohistochemical analysis. Results: A total of 1,449 DEGs were identified, including 775 upregulated and 674 downregulated genes. Prognostic analysis revealed 748 genes linked to clinical outcomes, with 19 hub genes identified. QPCR confirmed significant upregulation of four candidates, including BAIAP2L2, which was also elevated in malignant tissues. BAIAP2L2 knockdown significantly impaired migration, proliferation, and viability in PCa cells. Conclusion: This study highlights crucial molecular mechanisms in PCa progression, particularly the significance of BAIAP2L2 as a potential therapeutic target, warranting further investigation into additional hub genes for effective targeted strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.